NL-OMON34068
Completed
Not Applicable
Study of the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral dosing in healthy subjects including brain Serotonin Transporter (SERT) occupancy by Positron Emission Tomography (PET). - MAD/PET study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- chronische pijn aan beschadigde organen.
- Sponsor
- Eli Lilly
- Enrollment
- 51
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy male or female (post\-menopausal or surgically sterile), age between18 and 65 years, BMI between 19 and 32\.5 kg/m2, non\-smoker or light to moderate smoker, at screening state of healthy must satisfy the entry requirements.;Addition Part B:
- •Non\-exposure to any radiation for diagnostic reasons during work or during participation in a medical trial in the past year, non claustrophobic.
Exclusion Criteria
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1\.5 liters (for men)/1\.0 liters (for women) of blood in the 10 months prior the start of this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance after Multiple Oral Dosing of LY2623091 in Healthy Volunteerschronic kidney diseaseKidney failure10038430NL-OMON36630Eli Lilly32
Active, not recruiting
Phase 1
Safety, tolerability, and pharmacokinetics study of turoctocog alfa pegol injected under the skin in patients with haemophilia AEUCTR2016-002396-99-FRovo Nordisk A/S36
Active, not recruiting
Phase 1
Safety, tolerability, and pharmacokinetics study of turoctocog alfa pegol injected under the skin in patients with haemophilia AHaemophilia AMedDRA version: 19.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]EUCTR2016-002396-99-DEovo Nordisk A/S48
Active, not recruiting
Phase 1
Safety, tolerability, and pharmacokinetics study of turoctocog alfa pegol injected under the skin in patients with haemophilia AEUCTR2016-002396-99-BGovo Nordisk A/S36
Active, not recruiting
Phase 1
Safety, tolerability, and pharmacokinetics study of turoctocog alfa pegol injected under the skin in patients with haemophilia AEUCTR2016-002396-99-GBovo Nordisk A/S36